BEVAN GROUP PRACTICE
BEVAN WAY, WIDNES
HF 4
The percentage of patients with a current diagnosis of heart failure due to LVD who are currently treated with an ACE inhibitor or Angiotensin Receptor Blocker, who are additionally treated with a beta-blocker licensed for heart failure, or recorded as intolerant to or having a contraindication to beta-blockers.
| Indicator | Year | Numerator | Denominator | Ratio | Centile |
|---|---|---|---|---|---|
| HF 4 | 2010 | 25 | 36 | 69.4% | |
| HF 4 | 2011 | 26 | 33 | 78.8% | |
| HF 4 | 2012 | 40 | 46 | 87.0% | |
| HF 4 | 2013 | 38 | 40 | 95.0% | |
| HF004 | 2014 | 28 | 28 | 100.0% | |
| HF004 | 2015 | 49 | 54 | 90.7% | |
| HF004 | 2016 | 48 | 48 | 100.0% | |
| HF004 | 2017 | 54 | 55 | 98.2% | |
| HF004 | 2018 | 52 | 56 | 92.9% | |
| HF004 | 2019 | 55 | 63 | 87.3% | |
| HF004 | 2020 | 61 | 72 | 84.7% | |
| HF006 | 2021 | 69 | 81 | 85.2% | |
| HF006 | 2022 | 83 | 88 | 94.3% | |
| HF006 | 2023 | 78 | 81 | 96.3% |
